leadXpro enters collaboration on cryo-EM based new lead discovery with Bayer

Villigen, Switzerland, 5th April, 2017leadXpro AG announced today a collaboration to enable structure based drug discovery of membrane protein targets, facilitated by single particle cryo-Electron Microscopy (cryo-EM) with Bayer AG.


Under the terms of the agreement, leadXpro will provide their expertise in protein generation, sample preparation and high resolution cryo-electron microscopy to elucidate the structure, and interaction with small molecule ligands of membrane protein drug targets to facilitate the discovery and optimization of novel lead molecules.


Michael Hennig (CEO leadXpro) said: “We’re genuinely excited to be collaborating with Bayer on applying the cutting edge cryo-EM capabilities of our structure-based drug discovery platform. This potentially opens a door for discovering new lead molecules for membrane protein targets in many therapeutic areas. By applying high-end molecular imaging techniques these future drugs are now within our reach.”.


Financial terms of the partnership were not disclosed.


About leadXpro AG

leadXpro is a lead discovery company focusing on membrane protein drug targets. We are committed to the application of biophysical and structure-based methods for the discovery and optimization of next generation lead compounds. leadXpro’s technology platform enables structural determination of membrane proteins where classical crystallographic techniques fail, unlocking structure-based drug discovery for challenging targets. We capitalize on the knowledge regarding membrane protein structural biology and facilities of the Paul Scherrer Institute (PSI) with premium access to the synchrotron Swiss Light Source (SLS) and the Free Electron Laser (SwissFEL). Core expertise beyond X-ray include single particle cryo-electron microscopy (cryo-EM) and electron diffraction (ED). For more information, please visit www.leadxpro.com